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LETTERS TO THE EDITOR
Switch Maintenance
versus Second-Line
Treatment in Non-small
Cell Lung Cancer
To the Editor:
Three randomized phase III trials1–3
evaluated the role of “switch mainte-
nance” or “early second-line treatment,”
i.e., continuing treatment with a non–
cross-resistant drug, in patients with ad-
vanced non-small cell lung cancer who
did not progress after four cycles of plat-
inum-based doublets.4 In two of these
three studies, patients randomized in the
placebo arm could receive at progression
any second-line therapy,1,2 whereas in the
third trial,3 patients randomized in both
arms, immediately or at progression, were
treated with the same drug, i.e., docetaxel.
In the control arm of these three trials,
only 67%,1 72%,2 and 63%3 of enrolled
patients received a second-line therapy at
progression, respectively (Table 1). So,
more than one-third of patients did not
receive a second-line therapy due mainly
to the worsening of their general condi-
tions. This consideration reinforced the
goal of the switch maintenance approach
which is to recover all possible patients,
who do not progress during induction
therapy, to a second-line treatment.
Although data on dropout rates
were not reported in the three studies, they
can be derived from the survival curves:
the finding is that in the experimental arms
there was approximately one-third of
withdrawn patients. This is of great inter-
est because it means that there is a portion
of patients who do not benefit anyway
from second-line treatment and to whom a
further possible toxicity, related to the
switch maintenance treatment, could be
avoided. This consideration is reinforced
by the survival rate reported in the patients
who effectively received docetaxel in the
delayed arm of the study by of the Fidias
et al., which was identical to that regis-
tered in the immediate docetaxel arm.3
This led to the question regarding the
survival rate of the patients who effec-
tively received an active treatment in the
control arm after progression during pla-
cebo administration of the other two stud-
ies.1,2 Unfortunately, these data are lack-
ing. Moreover, in these two studies, the
percentage of patients randomized in the
placebo arm and who actually received
pemetrexed1 or an epidermal growth fac-
tor tyrosine kinase inhibitor (erlotinib or
gefitinib)2 was only 18% and 21%, respec-
tively. To date, pemetrexed and erlotinib
are licensed for switch maintenance ap-
proach based on the evidence that they
improve survival outcomes, but the need
of investigating the real role of switch main-
tenance versus second-line treatment at pro-
gression using the same drug in the experi-
mental and control arm remains unmatched.
Regulatory agencies requested such type of
trial, and for erlotinib this kind of trial is
going to start. This is the only way to con-
firm whether this approach is able to rescue
the percentage of patients otherwise lost to
second-line therapy also getting information
to select patients who could really benefit
from a further therapy.
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Classification of Large
Cell Neuroendocrine
Carcinoma
At the Cross Roads of
Small and Non-small
Cell Lung Cancer
To the Editor:
The European Respiratory Soci-
ety, American Thoracic Society, and the
International Association for Study of
Lung Cancer need to be complimented
for undertaking the much needed task of
reclassifying adenocarcinoma. The con-
sensus document has now been pub-
lished in a recent issue of Journal of
Thoracic Oncology.1 I have a comment
related to the section that discusses the
distinction of adenocarcinoma from
neuroendocrine carcinomas (NECs). It
has been stated that because neither the
prognosis nor treatment of non-small
cell lung cancer (NSCLC) is affected by
the presence of neuroendocrine markers,
routine immunohistochemistry (IHC)
and staining with these markers should
be avoided in the absence of histological
features suggestive of large cell NEC
(LC-NEC). However, it is becoming in-
creasingly evident that LC-NEC, as an
entity, tends to share some, if not all, of
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the biological aggressive properties that
are exhibited by small cell lung cancer
(SCLC).2 Also, the similarity in behav-
ior between LC-NEC and SCLC is ap-
parent not only at the molecular level
but also in terms of overall survival of
both these groups of patients. Five-year
survival rates as low as 32.1 and 33%,
respectively, have been reported for pa-
tients with stage I LC-NEC in two se-
ries.3–4 In addition, the clinical efficacy
of chemotherapy for LC-NEC and other
unresectable high-grade non-small cell
NECs has been shown to be comparable
with that for extensive disease SCLC.5 It
has also been shown recently that with
use of IHC, as many as 13% of poorly
differentiated cancers can be reclassified
as LC-NEC.2 The ultimate aim of pa-
thologists and cytologists is to avoid
giving a diagnosis of NSCLC-not other-
wise specified (NOS) and of treating
clinicians to offer the most appropriate
chemotherapeutic regimen. A diagnosis of
NSCLC-NOS poses a difficult scenario for
the treating clinician because it does not
allow him or her to practice histology-
guided treatment—a recent paradigm shift
in lung cancer management. Therefore, it
may be worthwhile to consider performing
IHC with neuroendocrine markers for all
biopsy or cytology specimens wherein the
best diagnosis that can be offered by the
pathologist or cytologist on conventional mi-
croscopy is NSCLC-NOS. This will help in
identifying the small but perhaps not insig-
nificant percentage of cases with LC-NEC
in whom a management strategy akin to
SCLC may be more appropriate than what is
followed for NSCLC-NOS.
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TABLE 1. Main Randomized Phase III Trials Investigating “Switch Maintenance” in Advanced Non-small Cell Lung Cancer
Author Treatment
No. of
Patients PFS (mo) OS (mo)
Dropouts in the
Experimental Arm
During First
Months
Post-
Discontinuation
of Anticancer
Systemic
Therapy
Patients of the Control
Arm Receiving as
Second-Line Therapy
the Same Drug of
Experimental Arm
OS (mo)
of Patients
Effectively
Treated
Ciuleanu
et al.1
Pemetrexed 441 4.3 13.4 NR 51% NA 13.4
vs HR 0.50; p  0.0001 HR 0.79; p  0.012
Placebo 222 2.6 10.6 NA 67% 18% NR
Cappuzzo
et al.2
Erlotinib 438 12.3a 12.0 NR 71% NA 12.0
vs HR 0.71; p  0.0001 HR 0.81; p  0.0088
Placebo 451 11.1a 11.0 NA 72% 21%b NR
Fidias
et al.3
Immediate
docetaxel
153 5.7 12.3 NR NR NA 12.3
vs p  0.0001 p  0.0853
Delayed
docetaxel
156 2.7 9.7 NA 63% 100% 12.5
a In weeks.
b Epidermal growth factor receptor tyrosine kinase inhibitors (erlotinib or gefitinib).
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; NR, not reported; NA, not applicable.
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